RT
Revier Therapeutics
Germany · Biotech
Revier Therapeutics develops small-molecule medicines targeting class IIa HDAC enzymes for cardiometabolic diseases.
Product
Revier Therapeutics is a Heidelberg biotechnology company developing treatments for cardiometabolic diseases. Its preclinical programmes focus on heart failure with preserved ejection fraction and atherosclerotic cardiovascular disease.
The company develops oral small molecules designed to selectively inhibit class IIa histone deacetylases. Its approach aims to act on disease-driving enzyme activity while preserving other biological functions. Revier is building the scientific, operational and clinical capabilities needed to advance these programmes.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | €6M | KHAN Technology Transfer Fund II — LeadHigh-Tech Gründerfonds — ParticipantRevier Invest Heidelberg — ParticipantVORNvc — Participant |